On February 29th, the @US_FDA issued guidance to provide a policy for novel coronavirus (COVID-19) molecular diagnostics tests developed & used in labs certified to perform high-complexity testing under CLIA prior to issuance of emergency use authorizations (EUA) for such tests

On February 29th, the @US_FDA issued guidance to provide a policy for novel coronavirus (COVID-19) molecular diagnostics tests developed & used in labs certified to perform high-complexity testing under CLIA prior to issuance of emergency use authorizations (EUA) for such tests
Source: Food and Drug Adminstration (FDA): CDRHNew - Category: Medical Devices Authors: Source Type: news